Dianthus Therapeutics (DE:87E)
FRANKFURT:87E
87E Stock Chart & Stats
€81.00
-€1.60(-6.11%)
At close: 4:00 PM EST
€81.00
-€1.60(-6.11%)
Day’s Range― - ―
52-Week Range€15.00 - €82.00
Previous CloseN/A
Volume0.00
Average Volume (3M)31.00
Market Cap
€4.57B
Enterprise Value€2.79B
Total Cash (Recent Filing)€1.11B
Total Debt (Recent Filing)€1.36M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 06, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume93
30 Day Avg. Volume31
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€114.65Price Target Upside41.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.23
Revenue Forecast (FY)€1.02M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and rising equity/assets provide durable financial flexibility for a clinical-stage biotech. This reduces near-term solvency risk, supports sustained R&D spend without immediate refinancing pressure, and strengthens the company's ability to fund multi-year trials and strategic options.
Extended Cash RunwayA roughly $1.2B cash position and recent financing extend operational runway materially, lowering near-term funding risk. This permits execution of Phase 3 and additional programs without immediate dilution, enabling milestone-driven de‑risking and optionality across multiple clinical readouts.
Positive Phase 3 Interim DataA 75% responder rate in an early Phase 3 interim supports the program's clinical hypothesis and could justify accelerated development decisions. Durable impact: strengthens competitive positioning in neuromuscular biologics and raises the probability that the lead asset will reach registrational milestones.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the company must rely on existing cash or future financing to fund operations. Over the medium term this elevates dilution and execution risk if clinical timelines slip or unexpected costs arise, constraining financial resilience.
Widening Operating LossesMaterially widening operating losses relative to revenue signal that current expense structure is not covered by incoming cash flows. Over multiple quarters this erodes returns on equity and increases dependency on capital markets, raising long-term investor risk if clinical progress stalls.
Early-stage Pipeline ConcentrationAs a primarily precommercial biotech, value hinges on a small set of clinical candidates. This concentration means long lead times to revenue and binary outcome risk from trials and regulatory review; failed readouts would materially impair future revenue prospects and strategy.
Dianthus Therapeutics News
87E FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was €15.00 and its highest was €82.00 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is €4.57B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 39 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on May 05, 2026. The company reported -€0.732 earnings per share for the quarter, beating the consensus estimate of -€0.923 by €0.191.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.73.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 54,666,233 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -€0.732 in its last earnings report, beating expectations of -€0.923. Following the earnings report the stock price went up 1.316%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DE:87E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€114.65 (41.54% Upside)
€114.65 (41.54% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.52%
12-Months-Change
Fundamentals
Return on Equity
-1.78%
Trailing 12-Months
Asset Growth
257.70%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
87E Stock 12 Month Forecast
Average Price Target
€114.65
▲(41.54% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Options Prices
Currently, No data available
---